Angion Biomedica logo

ANGN - Angion Biomedica Share Price

$17.34 -4.1  -18.9%

Last Trade - 9:00pm

Market Cap £438.4m
Enterprise Value £457.9m
Revenue £2.22m
Position in Universe 3257th / 6718
Unlock ANGN Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -18.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 4.03 1.49 -63.1%
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, AngionBiomedica Corp revenues increased from $791K to $2.4M. Netloss increased from $24.6M to $51.2M. Revenues reflect anincrease in demand for the Company's products and servicesdue to favorable market conditions. Higher net lossreflects General and administrative - Balanci increase from$4.6M to $12.9M (expense), Research and development -Balancing increase of 43% to $26.3M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ANGN Revenue Unlock ANGN Revenue

Net Income

ANGN Net Income Unlock ANGN Revenue

Normalised EPS

ANGN Normalised EPS Unlock ANGN Revenue

PE Ratio Range

ANGN PE Ratio Range Unlock ANGN Revenue

Dividend Yield Range

ANGN Dividend Yield Range Unlock ANGN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ANGN EPS Forecasts Unlock ANGN Revenue
Profile Summary

Angion Biomedica Corp. is a late-stage biopharmaceutical company. The Company focuses on discovery, development and commercialization of small molecule therapeutics to address acute organ injuries and fibrotic diseases. The Company’s lead product candidate is ANG-3777. Its pipeline includes ANG-3070, rho kinase 2 (ROCK2), and CYP11B2. Its ANG-3777 is a hepatocyte growth factor (HGF) mimetic it is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other organs, such as the lungs, central nervous system (CNS) and heart. It is also evaluating ANG-3777 for indications within acute lung injury (ALI), with focus on acute respiratory distress syndrome (ARDS), as well as acute CNS injuries. The Company’s other programs are for the treatment of fibrotic diseases, ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated April 6, 1998
No. of Shareholders: n/a
No. of Employees: 53
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 28,720,607
Free Float (0.0%)
Eligible for
ANGN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ANGN
Upcoming Events for ANGN
Frequently Asked Questions for Angion Biomedica
What is the Angion Biomedica share price?

As of 9:00pm, shares in Angion Biomedica are trading at $17.34, giving the company a market capitalisation of £438.4m. This share price information is delayed by 15 minutes.

How has the Angion Biomedica share price performed this year?

Shares in Angion Biomedica are currently trading at $17.34 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Angion Biomedica price has moved by % over the past year.

What are the analyst and broker recommendations for Angion Biomedica?

There are no analysts currently covering Angion Biomedica.

When will Angion Biomedica next release its financial results?

Angion Biomedica is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Angion Biomedica dividend yield?

Angion Biomedica does not currently pay a dividend.

Does Angion Biomedica pay a dividend?

Angion Biomedica does not currently pay a dividend.

When does Angion Biomedica next pay dividends?

Angion Biomedica does not currently pay a dividend.

How do I buy Angion Biomedica shares?

To buy shares in Angion Biomedica you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Angion Biomedica?

Shares in Angion Biomedica are currently trading at $17.34, giving the company a market capitalisation of £438.4m.

Where are Angion Biomedica shares listed? Where are Angion Biomedica shares listed?

Here are the trading details for Angion Biomedica:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ANGN
What kind of share is Angion Biomedica?

Based on an overall assessment of its quality, value and momentum, Angion Biomedica is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Angion Biomedica share price forecast 2021?

We were not able to load any forecast data for Angion Biomedica.

How can I tell whether the Angion Biomedica share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Angion Biomedica. Over the past six months, the relative strength of its shares against the market has been %. At the current price of $17.34, shares in Angion Biomedica are trading at 3.28% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Angion Biomedica PE Ratio?

We were not able to find PE ratio data for Angion Biomedica.

Who are the key directors of Angion Biomedica?

We were unable to find the directors for Angion Biomedica.

Who are the major shareholders of Angion Biomedica?

Here are the top five shareholders of Angion Biomedica based on the size of their shareholding:

EISA-ABC LLC Corporation
Percentage owned: 12.72% (3.65m shares)
Goldberg (Itzhak D) Individual Investor
Percentage owned: 7.45% (2.14m shares)
Venkatesan (Jay R M.D.) Individual Investor
Percentage owned: 4.46% (1.28m shares)
Ganzi (Victor F.) Individual Investor
Percentage owned: 2.55% (732k shares)
Neylan (John F) Individual Investor
Percentage owned: 0.14% (38.9k shares)
Similar to ANGN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.